Emerging Markets Pay 1% of U.S. Price for Gilead Sovaldi Bloomberg Developing countries such as Egypt, India and Brazil won discounts to pay 1 percent of the $84,000 price Gilead Sciences Inc. (GILD) is charging U.S. patients for its new hepatitis C drug. Wealthier countries such as Ukraine and China may not be so ... |
